MedPath

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Phase 2
Completed
Conditions
Lymphoma, B-Cell
Interventions
Registration Number
NCT00147121
Lead Sponsor
Haruhiko Fukuda
Brief Summary

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma

Detailed Description

Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell lymphoma, Phase 2/3 study was planned. Comparison(s): An intensified bi-weekly version by shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  1. Histological confirmed, low-grade B-cell lymphoma except mantle cell lymphoma and histologic transformation to DLBCL
  2. CD20-positive
  3. Ann Arbor CS III or IV
  4. Lymphoma cell count in PB≦10,000/mm3
  5. 20<=age<=69
  6. ECOG PS 0-2
  7. Bidimensionally measurable disease >1.5cm in a single dimension by CT scans
  8. No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy
  9. Normal BM, hepatic, renal, cardiac, and pulmonary function
  10. Written informed consent
Exclusion Criteria
  1. CNS involvement
  2. Glaucoma
  3. DM treated by insulin
  4. Uncontrollable HT
  5. AP, AMI
  6. Positive HBs antigen
  7. seropositive to HCV
  8. seropositive to HIV
  9. Interstitial pneumonitis, pulmonary fibrosis, or emphysema
  10. Severe infection
  11. Liver cirrhosis
  12. Double cancer
  13. Pregnant or lactating
  14. Patients who desire auto PBST after CR
  15. Patients treated with major tranquilizer or antidepressant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Rituximab + Standard CHOPRituximab+Standard CHOP
2Rituximab + Bi-weekly CHOPRituximab+bi-Weekly CHOP
Primary Outcome Measures
NameTimeMethod
CR rate (phase II)during the study conduct
PFS (phase III)during the study conduct
Secondary Outcome Measures
NameTimeMethod
ORR, PFS, OS, Safety (phase II)during the study conduct
OS, Safety (phase III)during the study conduct

Trial Locations

Locations (45)

Aichi Cancer Center Hospital

🇯🇵

Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi, Japan

Nagoya Daini Red Cross Hospital

🇯🇵

Nagoya,Showa-ku,Myoken-cho,2-9, Aichi, Japan

Ehime University Hospital

🇯🇵

Shitsukawa,Toon, Ehime, Japan

National Kyushu Cancer Center

🇯🇵

Fukuoka,Minami-ku,Notame,3-1-1, Fukuoka, Japan

University of Occupational and Environmental Health

🇯🇵

Kitakyushu,Yahatanishi-ku,Iseigaoka,1-1, Fukuoka, Japan

Mie University School of Medicine

🇯🇵

Tsu,Edobashi,2-174, Mie, Japan

NHO Kumamoto Medical Center

🇯🇵

Kumamoto,Ninomaru,1-5, Kumamoto, Japan

Kyoto Prefectural University of Medicine

🇯🇵

Kyoto,Kamigyo-ku,Kawaramachi-Hirokoji,465, Kyoto, Japan

Sasebo City General Hospital

🇯🇵

Sasebo,Hirasemachi,9-3, Nagasaki, Japan

Oita Prefectural Hospital

🇯🇵

Oita,Bunyo,476, Oita, Japan

Tokyo Metropolitan Komagome Hospital

🇯🇵

Bunkyo-ku,Honkomagome,3-18-22, Tokyo, Japan

Jikei University,Daisan Hospital

🇯🇵

Komae,Izumihoncho,4-11-1, Tokyo, Japan

Aichi Medical University

🇯🇵

Aichi-gun,Nagakute,Yazako,Karimata,21, Aichi, Japan

University of Fukui Hospital

🇯🇵

Yoshida-gun,Matsuoka,Shimoaizuki,23-3, Fukui, Japan

School of Medicine,Fukuoka University

🇯🇵

Fukuoka,Jonan-ku,Nanakuma,7-45-1, Fukuoka, Japan

Sapporo Hokuyu Hospital

🇯🇵

Sapporo,Shiroishi-ku,Higashi-sapporo,6-5-1, Hokkaido, Japan

National Cancer Center Hospital East

🇯🇵

Kashiwa,Kashiwanoha,6-5-1, Chiba, Japan

St.Marianna University School of Medicine,Yokohama City Seibu Hospital

🇯🇵

Yokohama,Asahi-ku,Yasashi-cho,1197-1, Kanagawa, Japan

Tohoku University Hospital

🇯🇵

Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi, Japan

Niigata Cancer Center Hospital

🇯🇵

Niigata,Kawagishi-cho,2-15-3, Niigata, Japan

Nagoya City University Hospital

🇯🇵

Nagoya,Mizuho-ku,Mizuho-cho,Kawasumi,1, Aichi, Japan

Nagoya University School of Medicine

🇯🇵

Nagoya,Showa-ku, Tsurumai-cho,65, Aichi, Japan

Nagoya Medical Center

🇯🇵

Nagoya,Naka-ku,Sannomaru,4-1-1, Aich, Japan

Akita University School of Medicine

🇯🇵

Akita,Hondo,1-1-1, Akita, Japan

Chiba Cancer Center Hospital

🇯🇵

Chiba,Chuo-ku,Nitona-cho,666-2, Chiba, Japan

National Hospital Organization Kyusyu Medical Center

🇯🇵

FukuokaChuo-ku,Jigyohama,1-8-1, Fukuoka, Japan

Ohta Nishinouchi Hospital

🇯🇵

Kohriyama,Nishinouchi,2-5-20, Fukushima, Japan

Gunma University

🇯🇵

Maebashi,Showa,3-39-15, Gunma, Japan

National Hospital Organization Hokkaido Cancer Center

🇯🇵

Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido, Japan

Imamura Bun-in Hospital

🇯🇵

Kagoshima,Kamoikeshinmachi,11-23, Kagoshima, Japan

Kanazawa Medical University

🇯🇵

Kahoku-gun,Uchinada-machi,Daigaku,1-1, Ishikawa, Japan

Kagoshima University,Faculty of Medicine

🇯🇵

Kagoshima,Sakuragaoka,8-35-1, Kagoshima, Japan

Tokai University School of Medicine

🇯🇵

Isehara,Shimokasuya,143, Kanagawa, Japan

Kumamoto University Medical School

🇯🇵

Kumamoto,Honjo,1-1-1, Kumamoto, Japan

Nagasaki Medical Center

🇯🇵

Oomura,Kubara,2-1001-1, Nagasaki, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki,Sakamoto,1-7-1, Nagasaki, Japan

Faculty of Medicine,University of Ryukyus

🇯🇵

Nakagami,Nishihara,Uehara,207, Okinawa, Japan

Faculty of Medicine, Saga University

🇯🇵

Saga,Nabeshima,5-1-1, Saga, Japan

Shiga Medical Center for Adults

🇯🇵

Moriyama,Moriyama,5-4-30, Shiga, Japan

Saitama Cancer Center

🇯🇵

Kita-adachi,Ina,Komuro,818, Saitama, Japan

Kyorin University School of Medicine

🇯🇵

Mitaka,Shinkawa,6-20-2, Tokyo, Japan

Hamamatsu University School of Medicine

🇯🇵

Hamamatsu,Handayama,1-20-1, Shizuoka, Japan

National Cancer Center Hospital

🇯🇵

Chuo-kum,Tsukiji, 5-1-1, Tokyo, Japan

Tokyo Medical University

🇯🇵

Shinjuku-ku,Nishi-shinjuku,6-7-1, Tokyo, Japan

Jikei University Hospital

🇯🇵

Minato-ku,Nishishinbashi,3-25-8, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath